Amicus Therapeutics, Inc. (FOLD) News

Amicus Therapeutics, Inc. (FOLD): $13.05

-0.20 (-1.51%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add FOLD to Watchlist
Sign Up

Industry: Biotech


Ranked

of 402

in industry

Filter FOLD News Items

FOLD News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

FOLD News Highlights

  • For FOLD, its 30 day story count is now at 2.
  • Over the past 23 days, the trend for FOLD's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • The most mentioned tickers in articles about FOLD are SYRS.

Latest FOLD News From Around the Web

Below are the latest news stories about AMICUS THERAPEUTICS INC that investors may wish to consider to help them evaluate FOLD as an investment opportunity.

Strength Seen in Syros Pharmaceuticals, Inc. (SYRS): Can Its 5.4% Jump Turn into More Strength?

Syros Pharmaceuticals, Inc. (SYRS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Yahoo | February 1, 2023

Amicus Therapeutics Reports Preliminary 2022 Revenue and Provides 2023 Strategic Outlook

Significant Growth in Demand with More Than 2,000 People Living with Fabry Disease on Galafold by End of 2022 2022 Full Year Revenue of ~$329M, Representing 16% YoY Growth at CER Continued Double-Digit Growth in Galafold Revenue of 12-17% at CER Expected in 2023 Multiple Approvals and Launches Expected in 2023 for AT-GAA in Pompe Disease On-Track to Achieve non-GAAP Profitability in 2H2023 PHILADELPHIA, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated glo

Yahoo | January 9, 2023

Amicus Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

PHILADELPHIA, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that Bradley Campbell, President and Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Monday, January 9, 2023 at 2:15 p.m. PT. A live audio webcast of the presentation can also be accessed via the investors section of the Amicus Therapeutics corporate website at https://ir.amicusrx.com/events-and-presentations. About Amicus Therapeut

Yahoo | January 3, 2023

12 Best 52-Week High Stocks To Buy Now

In this article, we will take a look at the 12 best 52-week high stocks to buy now. If you want to see more stocks in this selection, go to the 5 Best 52-Week High Stocks To Buy Now. The equity markets have been taking a beating this year as the Dow Jones Industrial Average […]

Yahoo | December 29, 2022

Market Sentiment Around Loss-Making Amicus Therapeutics, Inc. (NASDAQ:FOLD)

We feel now is a pretty good time to analyse Amicus Therapeutics, Inc.'s ( NASDAQ:FOLD ) business as it appears the...

Yahoo | December 26, 2022

CORRECTED-UPDATE 1-EU health regulator backs Amicus therapy for muscle disorder

The European Union's health regulator said on Friday it had recommended granting marketing authorization for Amicus Therapeutics Inc's experimental therapy to treat Pompe disease, a muscle disorder. Pompe disease is a rare genetic condition that leads to a buildup of the complex sugar glycogen, causing muscular impairment. The European Medicines Agency's decision comes amid delays for the drug in the United States.

Yahoo | December 16, 2022

Amicus Therapeutics Receives Positive CHMP Opinion for Pombiliti™ (cipaglucosidase alfa) for Late-Onset Pompe Disease

CHMP Adopts Positive Opinion Based Upon Complete Review of all Pre-Clinical, Clinical Studies and CMC Data CHMP Recommends Label for Long-Term Enzyme Replacement Therapy in Combination with Miglustat for both ERT-Experienced and Treatment-Naïve Adults Living with Late-Onset Pompe Disease CHMP Opinion for Miglustat, the Oral Enzyme Stabilizer Component of AT-GAA, Expected 2Q 2023 PHILADELPHIA, Dec. 16, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Committee

Yahoo | December 16, 2022

Why Is Amicus Therapeutics (FOLD) Up 13.7% Since Last Earnings Report?

Amicus Therapeutics (FOLD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Yahoo | December 7, 2022

Amicus Therapeutics to Present at the Stifel 2022 Healthcare Conference

PHILADELPHIA, Nov. 15, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in a fireside chat at the Stifel 2022 Healthcare Conference in New York, NY on Wednesday, November 16, 2022 at 9:45 a.m. E.T. A live audio webcast of the presentation can also be accessed via the investors section of the Amicus Therapeutics corporate website at https://ir.amicusrx.com/events-and-presentations. About Amicus Therapeutics Amicus Therapeutics (Nasdaq: F

Yahoo | November 15, 2022

Amicus Therapeutics Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues Lag

Amicus Therapeutics ( NASDAQ:FOLD ) Third Quarter 2022 Results Key Financial Results Revenue: US$81.7m (up 2.7% from 3Q...

Yahoo | November 9, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.73 seconds.